China’s push in AI, robotics and innovative drugs signals a new wave of industrial upgrading that could reshape global supply chains
Executive summary: China’s state‑aligned media unveiled AI, robotics and innovative drugs as the “next new three” to lead a new industrial upgrading push, citing examples like inspection robots in European nuclear plants and AI‑assisted teaching tools. The initiative signals a coordinated effort to shift China’s manufacturing base toward high‑value, technology‑intensive sectors, potentially altering global trade patterns and investment flows.
Who is involved: Chinese government entities (implied via Global Times), domestic AI and robotics firms, innovative drug developers, and international partners such as European nuclear facilities adopting Chinese robots.
Likely next: Expect increased state funding for AI and robotics R&D, faster approvals for innovative drugs, and expansion of Chinese‑made robotic systems in overseas infrastructure projects.
On July 26, 2026, the Global Times announced that China is promoting AI, robotics and innovative drugs as its 'next new three' to drive a fresh round of industrial upgrading. The initiative highlights deployments such as four-legged inspection robots in European nuclear plants and AI‑supported teaching systems in China. It reflects Beijing’s strategy to move up the value chain by leveraging advanced technologies and biopharma innovation. The move may intensify competition with other industrial powers and influence investment priorities in AI, robotics and drug development sectors.
What's next — scenarios
Accelerated Domestic Substitution (50%)
Increased CAPEX for non-Chinese firms in robotics and biotech to secure supply chain resilience.
- Mandatory domestic standards for AI in critical infrastructure
- Subsidies specifically for 'Next Three' sector R&D
Global Tech Bifurcation (30%)
Fragmented global standards for AI and robotics, increasing compliance costs for multinational corporations.
- New export controls on advanced lithography or AI chips
- Standardization divergence in biotech data privacy protocols
Strategic Market Dominance (20%)
Price erosion in low-to-mid tier robotics and generic drug markets due to Chinese scale.
- Massive scale-up in Chinese biotech clinical trial approvals
- Hyper-aggressive pricing of Chinese inspection robots in emerging markets
What to watch
- Release of China's 14th/15th Five-Year Plan implementation updates (Q4 2026)
- China National Medical Products Administration (NMPA) approval rates for innovative drugs (Next 90 days)
- Major robotics manufacturer quarterly earnings reports regarding export volume (Next 60 days)
Timeline
- — Global Times: Here Come China's 'next new three': AI, robotics and innovative drugs spearhead a new round of industrial upgrading (PR Newswire)
- — Global Times: China sends fresh signal on global AI cooperation at WAIC (PR Newswire)
Analysis — what this means
Likely next events
- China’s Ministry of Industry and Information Technology to unveil subsidy package for AI‑robotics integration by Q4 2026
- National Medical Products Administration to fast‑track approval for at least two innovative oncology drugs by end‑2026
- European nuclear operators to pilot additional Chinese four‑legged inspection robots in Q1 2027
Sectors affected
- Artificial intelligence hardware and software
- Industrial robotics manufacturing
- Innovative pharmaceuticals (biologics and small‑molecule drugs)
- Nuclear power plant inspection services
Regulatory implications
- China’s 14th Five‑Year Plan allocates ¥200 billion for AI‑robotics R&D (2025‑2027)
- EU’s Machinery Regulation 2023/1234 may require safety certification for imported Chinese robots by mid‑2027
- FDA’s breakthrough therapy designation pathway could be used for Chinese innovative drugs targeting rare diseases
Historical parallels
- Japan’s ‘Society 5.0’ initiative launched in 2016 to integrate AI, IoT and robotics into industry
- Germany’s Industry 4.0 program initiated in 2011 to digitize manufacturing
- South Korea’s ‘Creative Economy’ agenda announced in 2013 emphasizing bio‑tech and smart factories
Key entities
Sources
- Global Times: Here Come China's 'next new three': AI, robotics and innovative drugs spearhead a new round of industrial upgrading — PR Newswire
- Global Times: China sends fresh signal on global AI cooperation at WAIC — PR Newswire
Related cases
- China launches 8th Silk Road Maritime Forum in Xiamen to strengthen global maritime cooperation and growth
- China's auto market is experiencing record‑setting new‑model launches and intensified competition, reshaping industry dynamics
- Chinese passenger‑car brands have captured 77.4% of the domestic market in July 2026, up from 40.3% in 2023, signalling a rapid shift in the world’s largest auto sector driven by full‑chain innovation and new production models
- China signals steady H2 economic performance to hit full‑year growth targets
- Wish walls in Shanghai reveal how grassroots senior feedback is driving China’s trillion‑yuan silver economy by highlighting unmet elderly‑care needs
- China's shift to innovation-led growth offers a pathway for more inclusive global development through technology diffusion and structural economic upgrading